VIM-1, VIM-2, and GES-5 carbapenemases among pseudomonas aeruginosa isolates at a Tertiary Hospital in Istanbul, Turkey

Microbial Drug Resistance

Volumn 23, Issue 3, 2017, Pages 328-334

  Malkoçoǧlu, Gülşah ^a   Aktaş, Elif ^a   Bayraktar, Banu ^a   Otlu, Bariş ^b   Bulut, Mehmet Emin ^a  

^a Department of Pediatric Surgery   (Turkey)

^b INONU UNIVERSITY   (Turkey)

Author keywords

carbapenemase; GES 5; Pseudomonas aeruginosa; Turkey; VIM 1; VIM 2

Indexed keywords

AMIKACIN; AZTREONAM; BACTERIAL ENZYME; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; GES 5; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; UNCLASSIFIED DRUG; VIM 1; VIM 2; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; VIM-1 METALLO-BETA-LACTAMASE; VIM-2 BETA-LACTAMASE;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; ENZYME SYNTHESIS; FEMALE; GENETIC VARIABILITY; HUMAN; INFANT; INTENSIVE CARE UNIT; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR EPIDEMIOLOGY; NEWBORN; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEQUENCE ANALYSIS; TERTIARY CARE CENTER; TURKEY (REPUBLIC); GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTILOCUS SEQUENCE TYPING; PROCEDURES; PSEUDOMONAS INFECTIONS; TURKEY;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; DNA, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TERTIARY CARE CENTERS; TURKEY;

EID: 85017154605     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2016.0012     Document Type: Article

References (35)

1. Giamarellou, H., and G. Poulakou. 2009. Multidrugresistant Gram-negative infections: what are the treatment options? Drugs. 69:1879-1901.
2. Riera, E., G. Cabot, X. Mulet, M. Garcia-Castillo, R. del Campo, C. Juan, R. Canton, and A. Oliver. 2011. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J. Antimicrob. Chemother. 66:2022-2027.
3. Zavascki, A.P., A.L. Barth, A.L. Goncalves, A.L. Moro, J.F. Fernandes, A.F. Martins, F. Ramos, and L.Z. Goldani. 2006. The influence of metallo beta lactamase production on mortality in nosocomial Pseudomonas auroginosa infections. J. Antimicrob. Chemother. 58:387-392.
4. The Brooklyn Antibiotic Resistance Task Force. 2002. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on length of hospital stay. Infect. Control Hosp. Epidemiol. 23:106-108.
5. European Centre for Disease Prevention and Control. 2015. Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC, Stockholm.
6. Livermore, D.M., and N. Woodford. 2006. The betalactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 14:413-420.
7. Patel, G., and R.A. Bonomo. 2013. 'Stormy waters ahead'': global emergence of carbapenemases. Front.Microbiol. 4:48.
8. Oliver, A., X. Mulet, C. Lopez-Causape, and C. Juan. 2015. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist. Update. 21-22:41-59.
9. Cxakar, A. 2005. Identification of metallo-beta-lactamases in Pseudomonas aeruginosa strains isolated in Hacettepe University Hospitals by phenotypic and genotypic methods. Dissertation, Hacettepe University.
10. Bilen, S. 2010. Identifying of Pseudomonas aeruginosa and detection of metallo-beta-lactamase enzyme by phenotypic and genotypic methods. Dissertation, Hacettepe University.
11. Sarac, G. 2011. Carbapenem resistance in clinical P.aeruginosa isolates and detection of the resistance by phenotypic and genotypic methods. Dissertation, Mersin University.
12. Clinical and Laboratory Standards Institute. 2015. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fifth informational supplement M100-S25. CLSI, Wayne, PA.
13. van der Zwaluw, K., A. de Haan, G.N. Pluister, H.J. Bootsma, A.J. de Neeling, and L.M. Schouls. 2015. The carbapenem inactivation method (CIM), a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in gram-negative rods. PLoS One. 10:e0123690.
14. Doyle, D., G. Peirano, C. Lascols, T. Lloyd, D.L. Church, and J.D. Pitout. 2012. Laboratory detection of Enterobacteriaceae that produce carbapenemases. J. Clin. Microbiol. 50:3877-3880.
15. Poirel, L., I. Le Thomas, T. Naas, A. Karim, and P. Nordmann. 2000. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum b-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob. Agents Chemother. 44:622-632.
16. The European Committee on Antimicrobial Susceptibility Testing. 2013. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance (Version 1.0). Available at www.eucast.org.
17. Giske, C.G., L. Gezelius, O. Samuelsen, M. Warner, A. Sundsfjord, and N. Woodford. 2011. A sensitive and specific phenotypic assay for detection of metallo-b-lactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin. Clin.Microbiol. Infect. 17:552-556.
18. Kuzucu, C., R. Durmaz, B. Otlu, E. Aktas, H. Gulcan, and Z. Cizmeci. 2008. Species distribution, antifungal susceptibility and clonal relatedness of Candida isolates from patients in neonatal and pediatric intensive care units at a medical center in Turkey. New Microbiol. 31:401-418.
19. Cabrolier, N., M. Sauget, X. Bertrand, and D. Hocquet. 2015. Matrix-Assisted laser desorption ionization-Time of flight mass spectrometry identifies Pseudomonas aeruginosa high-risk clones. J. Clin. Microbiol. 53:1395-1398.
20. Trias, J., J. Dufresne, R.C. Levesque, and H. Nikaido. 1989. Decreased outer membrane permeability in imipenemresistant mutants of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 33:1202-1206.
21. Rizek, C., L. Fu, L.C. Dos Santos, G. Leite, J. Ramos, F. Rossi, T. Guimaraes, A.S. Levin, and S.F. Costa. 2014. Characterization of carbapenem-resistant Pseudomonas aeruginosa clinical isolates, carrying multiple genes coding for this antibiotic resistance. Ann. Clin. Microbiol. Antimicrob. 13:43.
22. Castanheira, M., L.M. Deshpande, A. Costello, T.A. Davies, and R.N. Jones. 2014. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseuomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries. J. Antimicrob. Chemother. 69: 1804-1814.
23. Potron, A., L. Poirel, and P. Nordmann. 2015. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int. J. Antimicrob. Agents. 45:568-585.
24. Kücükbasmaci, Ö ., K. Midilli, G. Issa, Ö Güven, and N. Gönüllü. 2010. A new multiplex PCR method for rapid detection of genes encoding VIMand IMP types ofmetallo beta lactamases. Turkiye Klinikleri J. Med. Sci. 30:1312-1316.
25. Mansur, A., S. Ay, B. Otlu, N. Güclüer, and Y. Ersoy. 2013. Investigation of metallo beta-lactamase production in carbapenem resistant Pseudomonas aeruginosa isolates. J. Turgut Ozal Med. Cent. 20:237-242.
26. Aksoy, D. 2013. Identification of metallo beta-lactamases in carbapenem resistant Pseudomonas aeruginosa strains by phenotypic and genotyping methods. Dissertation, Trakya University.
27. Ö zgümüs x, O.B., R. Ceylan, I. Tosun, C. Sandalli, K. Aydin, and I. Köksal. 2007. Molecular epidemiology of clinical Pseudomonas aeruginosa isolates carrying IMP-1 metallobetalactamase gene in a University Hospital in Turkey. Microb. Drug Resist. 13:191-198.
28. Iraz, M., A.O. Duzgun, A.C. Cicek, R.A. Bonnin, A. Ceylan, A. Saral, P. Nordmann, and C. Sandalli. 2014. Characterization of novelVIMcarbapenemase, VIM-38, and first detection of GES-5 carbapenem-hydrolyzing b-lactamases in Pseudomonas aeruginosa in Turkey. Diagn. Microbiol. Infect. Dis. 78:292-294.
29. Esenkaya Tasxbent, F., and M. Ö zdemir. 2015. The presence of OXA type carbapenemases in Pseudomonas strains: first report from Turkey. Mikrobiyol. Bul. 49:26-34.
30. Bebrone, C., P. Bogaerts, H. Delbruck, S. Bennink, M.B. Kupper, R. Rezende de Castro, Y. Glupczynski, and K.M. Hoffmann. 2013. GES-18, a new carbapenem-hydrolyzing GES-Type b-lactamase from Pseudomonas aeruginosa that contains Ile80 and Ser170 residues. Antimicrob. Agents Chemother. 57:396-401.
31. Poirel, L., G.F. Weldhagen, C. De Champs, and P. Nordmann. 2002. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum b-lactamase GES-2 in South Africa. J. Antimicrob. Chemother. 49:561-565.
32. Wang, C., P. Cai, D. Chang, and A.A. Mi. 2006. Pseudomonas aeruginosa isolate producing the GES-5 extended-spectrum b-lactamase. J. Antimicrob. Chemother. 57:1261-1262.
33. Labuschagne, J., G.F. Weldhagen, M.M. Ehlers, and M.G. Dove. 2008. Emergence of class 1 integron-Associated GES-5 and GES-5-like extended-spectrum b-lactamases in clinical isolates of Pseudomonas aeruginosa in South Africa. Int. J. Antimicrob. Agents. 31:527-530.
34. Picao, R.C., L. Poirel, A.C. Gales, and P. Nordmann. 2009. Diversity of b-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing blood stream infections in Brazil. Antimicrob. Agents Chemother. 53:3908-3913.
35. Nordmann, P., L. Poirel, and L. Dortet. 2012. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 18:1503-1507.